Ion Exchange (India) Ltd Q4 FY26: The ₹60 Crore Supply Chain Mirage and the Roha Asset Gravity

At a Glance

A severe operational bottleneck has emerged behind the traditional stability of India’s premier water treatment franchise. Ion Exchange (India) Ltd concluded the final quarter of the financial year with an operating income of ₹863.30 crore, representing a modest year-on-year expansion of 3.44%. However, this minor topline growth masks an acute compression in core operational profitability, as operating EBITDA collapsed by 76.81% to ₹19.90 crore, dragging operating margins down to a skeletal 2.31%. Investors are faced with a dual reality: a robust consolidated backlog of ₹2,833 crore providing clear structural visibility, contrasted against severe near-term margin degradation from delayed high-value international engineering dispatches and heavy structural commissioning costs.

The primary operational friction points trace directly to the ongoing West Asia geopolitical crisis, which deferred approximately ₹60 crore of highly profitable export engineering shipments, forcing a less favorable, higher-cost domestic mix into execution. Concurrently, the comprehensive capitalization of the greenfield resin facility in Roha has introduced significant structural pressure, driving depreciation higher by 66.10% to ₹19.60 crore and finance costs up to ₹10.80 crore for the quarter. While the recent global testing certification from the Water Quality Association unlocks the crucial US drinking water export channel, the near-term return profile remains heavily penalized by asset-underutilization. Capital misallocation risks often manifest not through a failure of strategic intent, but through the temporal gap between expensive structural asset commissioning and final operational optimization.

Introduction

Ion Exchange (India) Ltd is moving through a complex transition phase, attempting to shift from a legacy domestic engineering contractor into a high-margin, global specialty chemical and membrane systems producer. Originally established in 1964 as a subsidiary of Permutit (UK) before transitioning to an independent Indian entity in 1985, the company has spent decades engineering commercial water infrastructure.

Structurally, management is attempting to scale three distinct platforms simultaneously: a large-scale industrial projects arm, an expanding specialty chemical plant network, and a consumer-facing retail franchise. The ongoing operational challenge is balancing the long working-capital cycles of state-sponsored infrastructure with the immediate, front-loaded capital expenditure required to establish world-class chemical manufacturing capacities.

Business Model: WTF Do They Even Do?

Ion Exchange acts as the heavy industrial kidney of corporate manufacturing, specializing in pulling clean process water out of environmental systems and pushing treated effluent back in without violating environmental law. The operations are organized across three distinct, occasionally conflicting segments:

• Engineering (58% of FY26 Revenue): The legacy core. This segment designs and builds massive, capital-intensive water treatment infrastructure, including sea water desalination systems, recycling loops, and Zero Liquid Discharge plants for heavy industrial players like Reliance and NTPC.
• Chemicals (29% of FY26 Revenue): The intended profitability engine. This division manufactures ion exchange resins and water treatment specialty chemicals. It is a business defined by long product qualification cycles, strict international quality benchmarks, and high asset productivity once optimal utilization is achieved.
• Consumer Products (13% of FY26 Revenue): The retail outreach. This branch sells municipal and residential water purification units to homes, hotels, and hospitals under marketing initiatives like the “Bharat Ka Paani” campaign. It remains an investment-heavy, lower-margin distribution game.

Financials Overview

Figures are consolidated, in ₹ crore.

What is Management Promising in the Coming Quarters?

The core performance of the engineering business is structurally sound, supported by a standalone engineering order book of ₹2,643.30 crore as of March 31, 2026. Management noted that full-year order inflows grew by 40% compared to the prior fiscal year, providing visible revenue coverage for FY27 and FY28. Regarding the margin-depleting legacy exposures, the Sri Lanka project is nearing final closure with an outstanding balance of ₹90 crore, expected to fully wrap up by Q2 FY27.

Conversely, the complex UP Jal Jeevan Mission project—holding an outstanding value of ₹320 crore—remains constrained. Management explicitly stated that approximately 30% of the scope is pending, and they will deliberately throttle execution to match actual cash collections to protect working capital, pushing final completion out past the next financial year.

On the chemicals side, the newly commissioned Roha plant is expected to gradually scale up toward a targeted 25% utilization rate for